Design: Phase 3, randomised, double-blind, placebo-controlled, 80 weeks
Population: 1,152 adults with type 2 diabetes and BMI 27 kg/m² or above
Primary outcome: Percentage change in body weight at week 80
Effect: −18.8% on 12 mg vs −5.1% on placebo; difference −13.8% (95% CI −15.8 to −11.8)

TRIUMPH-2 was a double-blind, placebo-controlled phase 3 trial at 92 centres in eight countries. It enrolled 1,152 adults with type 2 diabetes and a BMI of 27 or more, most already on oral glucose-lowering drugs, and randomised them to weekly retatrutide 4, 9 or 12 mg or placebo. Retatrutide acts on GIP, GLP-1 and glucagon receptors.

At 80 weeks, body weight fell 11.9%, 16.8% and 18.8% with the three doses, against 5.1% with placebo. The placebo-adjusted difference on 12 mg was −13.8%. That is a larger loss than people with diabetes usually achieve on incretin drugs, a group in whom weight typically responds less well than in obesity without diabetes.

The cost is tolerability. Diarrhoea affected about a third on the two higher doses and nausea up to 28%. Hypotension (up to 6%) and dysaesthesia, an altered skin sensation (up to 7%), were also more common than on placebo. Stopping for adverse events reached 12% on 9 mg.

Retatrutide is not approved anywhere yet, and its regulatory status in India is unknown. For now this tells you what the next class may offer, and which side effects to ask about when it arrives.

Retatrutide is investigational; it is not a prescribing option yet.
Expect higher-dose incretin therapy to cause diarrhoea or nausea in a third of patients early on.
Ask about light-headedness and check lying and standing blood pressure in patients on several antihypertensives.
Record new tingling or altered skin sensation; dysaesthesia was a signal in this trial.
When weight falls this far, review sulfonylurea and insulin doses to avoid hypoglycaemia.

Why it matters

Weight loss in diabetes has long lagged weight loss in obesity alone; this narrows that gap.

The statistics, in plain English

The −13.8% figure is the extra weight lost beyond placebo, with a 95% confidence interval of −15.8% to −11.8%; even the smallest plausible effect is large. These results use the 'treatment regimen' estimand, which counts people who stopped the drug, so it reflects real use rather than perfect adherence.